Cytokine Release Syndrome (Cytokine Storm) – Drugs In Development, 2024
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Cytokine Release Syndrome (Cytokine Storm) – Drugs In Development, 2024 report and make more profitable business decisions.
Cytokine release syndrome (CRS) is a systemic inflammatory response, potentially life-threatening and triggered by various factors like infections and specific drugs. It can occur following the administration of natural and bispecific antibodies, as well as adoptive T-cell therapies for cancer. CRS is characterized by elevated levels of cytokines, including interleukin (IL)-6 and interferon γ. Tocilizumab, an anti-IL-6 receptor antibody, coupled with corticosteroids, has shown promise in reversing CRS, but its early and aggressive use may compromise the efficacy of immunotherapy. Therefore, current strategies aim to judiciously administer immunosuppressive therapy, focusing on patients facing severe consequences of the syndrome.
The Cytokine Release Syndrome (Cytokine Storm) drugs in development market research report provide comprehensive information on the therapeutics under development for Cytokine Release Syndrome (Cytokine Storm), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cytokine Release Syndrome (Cytokine Storm) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- Therapeutics in Development: Covering 19 molecules, with 19 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Cytokine Release Syndrome (Cytokine Storm) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Cytokine Release Syndrome (Cytokine Storm) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Cytokine Release Syndrome (Cytokine Storm) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Antengene Corp LtdBioXcellerator Inc
Cellics Therapeutics Inc
Chengdu Zeling Biomedical Technology Co Ltd
Crossfire Oncology Holding BV
CytoAgents Inc
Enlivex Therapeutics Ltd
F. Hoffmann-La Roche Ltd
FibroGenesis LLC
HighTide Therapeutics Inc
Incyte Corp
JSR Life Sciences LLC
Poolbeg Pharma Plc
Prestige BioPharma Ltd
SFA Therapeutics Inc
TheraBioPharma Inc
Tianjin Hemay Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co Ltd